Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions By Ogkologos - June 23, 2026 205 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the WU-KONG28 study Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR ¿Qué es la escasez de medicamentos y cómo puede afectar a... June 30, 2023 An Updated Overview of Estimates for Cancer Incidence and Mortality in... June 23, 2022 Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... July 12, 2024 NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous... June 8, 2021 Load more HOT NEWS A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer Man Spent 20 Years Tracking Down And Buying His Late Mother’s...
